research The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Finasteride Treatment of Hair Loss in Women
Finasteride may help some women with hair loss, but better options exist.
research Comparison of finasteride (proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition
Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
research Acute and 30-day oral toxicity studies of a novel coccidiostat – ethanamizuril
Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
research COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
research Major role for 5-alpha reductase inhibitors in the aging male
5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
research Anti-nociceptive and anti-inflammatory properties of 5alpha-reductase inhibitor finasteride in experimental animals
Finasteride helps reduce pain and inflammation in animals.
research Minoxidil and male-pattern alopecia: a potential role for a local regulator of sebum secretion with vasoconstrictive effects?
Minoxidil, a common hair loss treatment, might work by counteracting a hormone that reduces hair growth and promotes hair loss.
research Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo‐controlled, double‐blind, noninferiority study
New 5% minoxidil formula safely and effectively treats male hair loss.
research 050 Evaluation of 3 month data for the use of erenumab for chronic migraine in Glasgow
Erenumab significantly reduced migraine days or severity in most patients after 3 months.